SCHEMBL5418005

SCHEMBL5418005

CN(C)CCN1CCC(N2CCc3cnc(O)c4cccc2c34)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
PTK2B Q14289 1/20 0.36
ESR2 Q92731 1/20 0.36
DRD2 P14416 6/20 0.34
DRD3 P35462 6/20 0.34
ABL1 P00519 1/20 0.33
EGFR P00533 1/20 0.33
LCK P06239 1/20 0.33
SRC P12931 1/20 0.33
ABL2 P42684 1/20 0.33
BRD4 O60885 1/20 0.33
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
BRDT Q58F21 1/20 0.33
RAD52 P43351 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MELK Q14680 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5406936 0.94 KDM4E (0.35) KDM4EALDH1A1LMNAMAPTPTK2B
SCHEMBL5418313 0.94 HTR4 (0.35) KDM4EALDH1A1LMNAMAPTPTK2B
SCHEMBL5410382 0.90 KDM1A (0.39) DRD2DRD3ABL1EGFRLCK
SCHEMBL5410130 0.89 DRD2 (0.36) KDM4EALDH1A1LMNAMAPTDRD2
SCHEMBL5423943 0.88 NOS3 (0.41) KDM4EALDH1A1LMNAMAPTDRD2
SCHEMBL5421510 0.87 NOS3 (0.35) KDM4EDRD2DRD3ABL1EGFR
SCHEMBL5425324 0.86 CARM1 (0.38) HRH3
SCHEMBL5428066 0.86 NOS3 (0.36) KDM4EALDH1A1LMNADRD2DRD3
SCHEMBL5423993 0.85 DRD2 (0.34) DRD2DRD3ABL1EGFRLCK
SCHEMBL5407123 0.84 DRD2 (0.35) KDM4EDRD2DRD3RAD52L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160894-B2 Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine ASAHI KASEI PHARMA CORPORATION (JP) 2007-01-09 US claimed
EP-1632492-A1 TRICYCLIC COMPOUND Asahi Kasei Pharma Corporation (JP) 2006-03-08 EP claimed
US-20050096310-A1 Tricyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2005-05-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096310-A1 Tricyclic compound MYLK3, CSNK1A1L, MYLK KDM4E 3665/4885ALDH1A1 3204/4885LMNA 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.